FGF21 and metabolic dysfunction-associated steatohepatitis: These FGF21 analogues have a longer half-life than the natural protein and have been tested in patients with hypertriglyceridemia but also in patients with NAFLD and non-alcoholic steatohepatitis (NASH) [47, 48].